HEAD-TO-HEAD COMPARISON
Compound Semaglutide vs ZepboundSemaglutide vs Tirzepatide
Verdict: Zepbound (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Compound Semaglutide (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Compound Semaglutide has a longer real-world track record and broader insurance coverage in some plans.
Side-by-side comparison
| Compound Semaglutide | Zepbound | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | 503A / 503B pharmacies | Eli Lilly |
| FDA approval | Not approved as finished product | 2023 |
| Indication | Not an FDA-approved finished product. 503A compounding is restricted now that the FDA has declared the semaglutide shortage resolved. | Chronic weight management for adults with BMI 30+, or 27+ with at least one weight-related comorbidity |
| Starting dose | Step 1 of 5 | Step 1 of 6 |
| Maintenance target | 2.4 mg/week | 15 mg/week |
| Titration length | ~17 weeks | ~21 weeks |
| Mean weight loss | Same molecule as Wegovy/Ozempic; outcomes track brand when correctly compounded | ~20.9% mean at 72 weeks (SURMOUNT-1) |
| HbA1c reduction | Same as branded semaglutide | ~2.2 pp (off-label in T2D) |
| Cost (US list) | Historically $200 to $400 / mo during shortage | ~$1,060 / mo US list |
| Insurance | Not covered | Patchy for obesity indication |
Who should pick which
- Pick Zepbound if the primary goal is weight management with an obesity-indicated label. Higher maintenance dose and stronger trial weight-loss data.
- Consider Compound Semaglutide only with a clinician's prescription and a verified Certificate of Analysis from the supplying pharmacy. Cost is meaningfully lower than Zepbound but supply has narrowed since FDA shortage resolution.
- Consider Zepbound (tirzepatide) if mean weight loss in published trials is the deciding factor. Dual GIP + GLP-1 mechanism produces the largest effect size in head-to-head data.
Switching between the two
Transitioning between semaglutide and tirzepatide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Open Semaglutide Dose Calculator → Compare full titration schedules side by sideFrequently asked
Is Compound Semaglutide better than Zepbound?
Zepbound (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Compound Semaglutide (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Compound Semaglutide has a longer real-world track record and broader insurance coverage in some plans.
Can I switch from Compound Semaglutide to Zepbound?
Transitioning between semaglutide and tirzepatide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Does Compound Semaglutide produce more weight loss than Zepbound?
Compound Semaglutide: Same molecule as Wegovy/Ozempic; outcomes track brand when correctly compounded. Zepbound: ~20.9% mean at 72 weeks (SURMOUNT-1). Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Compound Semaglutide priced differently from Zepbound?
Compound Semaglutide costs Historically $200 to $400 / mo during shortage; Zepbound costs ~$1,060 / mo US list. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Compound Semaglutide or Zepbound?
Both Compound Semaglutide and Zepbound address T2D-relevant pathways via GLP-1 receptor activity. Trial HbA1c reductions: Compound Semaglutide Same as branded semaglutide; Zepbound ~2.2 pp (off-label in T2D).
Related
For research informational use only. Not medical advice. Zepbound is a registered trademark of its manufacturer. Consult a qualified healthcare provider for clinical decisions.